| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3193744 | Annals of Allergy, Asthma & Immunology | 2006 | 11 Pages |
Abstract
Significant differences and large effect sizes favoring omalizumab were observed despite the control group receiving active, guideline-consistent treatment. The meta-analysis findings demonstrate that omalizumab treatment provides QOL benefits in patients with moderate-to-severe allergic asthma.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Kimberly MPP, Sarah MSc, Julia PhD, Dennis A. PhD,